Navigation Links
Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
Date:2/8/2012

er two applied at five clinic visits.  Safety and tolerability were assessed by adverse event reports, physical examination, electrocardiogram and clinical laboratory tests. Patients with certain cardiac conditions were excluded from the study along with patients taking certain medications.

Study Results

On all six scales, DMQ 45/30 mg was significantly superior to placebo, including the primary efficacy analysis, which utilized mixed-effects modeling to test all scores on an 11-point numerical Pain Rating Scale (p < 0.0001). Sensitivity analyses gave consistent results. Efficacy versus placebo was also seen for diary ratings of present pain intensity, and pain interference with sleep and with activities (all p < 0.0001). Among clinic-visit assessments, DMQ 45/30 mg demonstrated greater leg-pain relief (p = 0.0002) and greater reduction of leg-pain intensity (p = 0.0286) versus placebo. The efficacy of DMQ 30/30 mg was numerically less than for 45/30 mg but for most outcomes remained significantly greater versus placebo. Adverse events were mostly mild or moderate and of expected types. Discontinuation for adverse events in the DMQ groups was at least twice as common as placebo.

About Diabetic Peripheral Neuropathic Pain

Diabetic neuropathic pain, one of the most debilitating forms of pain, is caused by nerve damage that can result from diabetes. It is often described as burning, tingling, stabbing, or pins and needles in the feet, legs, hands or arms. The most frequent form, estimated to affect approximately 50% of diabetic patients, is a distal symmetric polyneuropathy that can involve both small and large sensory fibers. The associated pain, estimated to affect approximately 25% of DPN patients, can be severe and disabling.

About AVP-923

AVP-923 is a combination of two well-characterized compounds: the active ingredient dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagoni
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
2. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
3. Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
4. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
5. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
6. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
7. Avanir Pharmaceuticals to Participate in Two Investor Conferences
8. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
9. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
10. Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
11. Avanir Pharmaceuticals Announces Appointment of Dr. Joao Siffert as Senior Vice President Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 25, 2014 ... Instruments Market by Power Source (Electric, Battery, Pneumatic), ... Cables, Blade, Burr, Cart), by Application (Orthopedic, ENT, ... published by MarketsandMarkets, the global Powered Surgical Instruments Market ... $1.6 Billion in 2014 and is expected to ...
(Date:11/26/2014)... , Nov. 25, 2014 ... focused on the development of mobile diagnostic ... testing in hospital and pre-hospital settings, today ... (ISO) 13485:2003 certification.  The certification was awarded ... of the world,s leading certification bodies. ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen ... AZN ) today announced that AMAGINE-2 TM , a pivotal, ... more than 1,800 patients with moderate-to-severe plaque psoriasis, met its ... and placebo at week 12. Brodalumab 210 mg given every ... shown to be superior to Stelara on the primary endpoint ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
(Date:11/27/2014)... DC (PRWEB) November 27, 2014 “Wekho” was ... features the latest and coolest mobile applications on the iOS, ... and host of NewsWatch, conducted the app review ... locations instead of people. , An interesting new way to ... iOS and Android devices. It’s called Wekho and it’s ...
(Date:11/27/2014)... 27, 2014 This is a ... Insulin industry. For an overview analysis, the report ... industry chain structure, industry overview, policy analysis, and ... industry covers information on policy, plans for ... structure and much more. , This ...
(Date:11/27/2014)... At The Little Gym, we know that ... no surprise when a recent study confirmed that regular ... Journal of Pediatrics found that “Promoting physical ... the school years may be important not only for ... monitored two groups of children; those that were engaging ...
(Date:11/27/2014)... November 27, 2014 The Emerald Cup ... Up-Close Look At This Year’s Entries | SKUNK Magazine ... Stay For Two At Their Resort, Pure Garden, In ... or L.A.-based Hempcon, The Emerald Cup is presented by ... draws much of California’s original cannabis industry." – SFGate, ...
(Date:11/27/2014)... 27, 2014 In addition to a ... important gift home this holiday season and become educated ... Visiting with relatives over the holidays may raise questions ... Although some change in cognitive ability can occur with ... normal aging. Recognizing the difference between normal aging and ...
Breaking Medicine News(10 mins):Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 2Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 3Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 4Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 2Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 3Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 4Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 5
... cardiovascular disease can all cloud symptoms, study says , , WEDNESDAY, ... (MS) may be delayed in people if they have other ... high blood pressure and high cholesterol appeared to mask early ... concluded the study, published in the Oct. 29 online issue ...
... CRP may only reflect existing cardiovascular trouble, study finds ... levels of C-reactive protein do not increase the ... suggests. , The inflammation-linked molecule has gained prominence in ... But the question remained -- does the protein only ...
... Preliminary results from U.S.,Department of Defense-funded clinical trials ... rooms are contaminated with high levels of,potentially dangerous ... the Interscience Conference on Antimicrobial Agents and Chemotherapy,(ICAAC) ... that objects in,closest proximity to patients, such as ...
... 29 Texcel, a leading,provider of custom ... its innovative new StimX programmable, implantable,stimulation system., ... and development of specialty,stimulation therapies, the StimX ... platform., The StimX system,s programmable stimulation ...
... Rochester NY Growth Company, boasts premiere pharmacy services innovation. ... ... 2008 -- PharmaSmart International , an innovative health management ... levels, worksites, medical facilities and specialty care centers boasts an ...
... to the gym on a regular basis right after a ... the gym one day, then the next day and the ... that the negative effects of skipping exercise can occur in ... to a sedentary lifestyle can quickly lead to symptoms of ...
Cached Medicine News:Health News:Other Health Problems Can Delay MS Diagnosis 2Health News:Key Blood Test Protein May Not Cause Heart Disease 2Health News:Key Blood Test Protein May Not Cause Heart Disease 3Health News:First Results from Hospital Trials Show Pathogens Stay Close to Patients 2Health News:Texcel Introduces Innovative Programmable, Implantable Stimulation System for R&D of Specialty Stimulation Therapies 2Health News:PharmaSmart International, Inc. Redefines Blood Pressure Management through Technology and Pharmacy Focused Patient Services 2Health News:PharmaSmart International, Inc. Redefines Blood Pressure Management through Technology and Pharmacy Focused Patient Services 3Health News:PharmaSmart International, Inc. Redefines Blood Pressure Management through Technology and Pharmacy Focused Patient Services 4Health News:New study indicates that exercise prevents fatty liver disease 2
... is equipped with a new 1/2" Progressive ... excellent sensitivity (1280 (H) x 960 (V) ... uncompressed, high-resolution, digital color images and features ... an exposure range from 1/100,000 to 17.5 ...
... DP70 brings you the latest in imaging technology ... The DP70 offers high resolution, high sensitivity, and ... demanding applications, including fluorescence. CCD ... Bit Depth - 36-bit ...
4 megapixel zoom digicam with a 4x optical zoom, Effective pixels:4.0 million CCD:1/1.8-in. type (4.13 million total pixels), Max Image size:2272 (2,272 x 1,704 pixels), Lens:4x Zoom-Nikkor; f = 7.85...
... superb stand-alone digital camera with networking capability ... or remote locations. Image acquisition and camera ... operates independently or attaches directly to a ... to capture and transfer images. Sharing images ...
Medicine Products: